FDA approves Cayston

FDA approved an NDA from Gilead Sciences Inc. (NASDAQ:GILD) for Cayston aztreonam lysine to improve respiratory symptoms in cystic fibrosis (CF) patients with Pseudomonas aeruginosa infections. Gilead plans to launch the inhaled cephalosporin antibiotic in the U.S. by the end of next week. Gilead, which made the announcement after market close, was off $0.96 to $47.88 on Monday. ...